מתוך medicontext.co.il
LONDON (Reuters Health) – Britain's National Institute for Clinical Excellence will issue guidance on Wednesday on the use of the anti-obesity drug sibutramine (Reductil/Meridia), the cost-effectiveness watchdog said on Monday.
Approval is thought likely as NICE has already recommended, within limits, Roche's more expensive rival product Xenical (orlistat), which has been available in Britain since September 1998.
Abbott began marketing Knoll's sibutramine in the UK in May this year, undercutting the price of Roche's rival product Xenical (orlistat), which has been available in Britain since September 1998.
The National Health Service price for 28 days of treatment with Reductil is 35 pounds for a 10 mg dose and 39.09 pounds for a 15 mg dose, compared with 41.16 pounds for Xenical.
NICE recommended Xenical in March this year, but insisted that the product be limited to adults up to 75 years old who have lost at least 2.5 kilograms by dieting in the month before starting therapy.
In addition, patients should be overweight with a body mass index (BMI) of 28 or more and have another serious illness such as type 2 diabetes, hypertension or high cholesterol; or have a BMI of 30 with no associated illnesses.
Therapy should only continue for more than 3 months if patients lose at least 5% of their body weight, and only continue for more than 6 months if they lose at least 10%.
Treatment should not normally continue beyond 12 months and never beyond 24 months, NICE added in its guidance to the National Health Service.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!